Results 61 to 70 of about 11,074 (164)

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, Volume 6, Issue 10, October 2026.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.

, 2022
Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell lung cancer (NSCLC). Methods: Final
Walton, LJ, Lin, HM, Cranmer, H, Reckamp, KL, Zhang, P, Fahrbach, K, Kay, S, Popat, S, Wu, Y, Cichewicz, A, Camidge, DR, Neupane, B   +11 more
core   +1 more source

Sequence Inversion Dictates the Antiproliferative Activity of Bidirectional Tryptophan‐Containing Dipeptide Libraries

Journal of Peptide Science, Volume 32, Issue 10, October 2026.
Reversing the peptide backbone sequence of novel tryptophyl‐dipeptides uncovers profound changes in synthetic accessibility and antineoplastic profiles against human solid tumors. Phenotypic screening identifies a conformationally restricted lead architecture that achieves sub‐micromolar growth inhibition, confirming sequence topology as a critical ...
J. Benamer Díaz, Adam N. Khan, Aday González‐Bakker, José M. Padrón   +3 more
wiley   +1 more source

Effects of crizotinib or alectinib on firing rate.

, 2015
Effects of crizotinib or alectinib on firing rate.
Makoto Kaneda (168546), Toshiyuki Ishii (53332), Shunichiro Iwasawa (782964), Yuichi Takiguchi (395734), Akemi Maeda (782966), Ryota Kurimoto (782965)   +5 more
core   +1 more source

A Bayesian Adaptive Design for Assessing Treatment Effect Consistency in Bridging Studies

Statistics in Medicine, Volume 45, Issue 23-24, October 2026.
ABSTRACT Bridging studies serve as an efficient approach to evaluate the applicability of findings from an original study to a new population. We propose a Bayesian adaptive design for bridging studies with time‐to‐event endpoints, aiming to assess the consistency of treatment effects with those observed in the original study. The design adopts a group
Xinyi He, Dan Zhao, Zhaoyang Teng, Hua Liu, Ying Yuan   +4 more
wiley   +1 more source

Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis [PDF]

, 2018
The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase （ALK）-positive advanced non-small cell lung cancer still remains to be elucidated.
MANABE, Ryo, KUSUMOTO, Sojiro, OHMORI, Tohru, TANAKA, Akihiko, YAMAOKA, Toshimitsu, ANDO, Koichi, SAGARA, Hironori, OHNISHI, Tsukasa   +7 more
core   +2 more sources

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2089-2096, October 2026.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, John Gaughan, Elyce Cardonick   +2 more
wiley   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

npj Precision Oncology
Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lymphoma kinase ...
Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura   +10 more
doaj   +1 more source

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

PLoS ONE, 2020
BackgroundWe sought to assess the relative effects of individual anaplastic lymphoma kinase (ALK) inhibitors for the treatment of non-small cell lung cancer (NSCLC).MethodsWe searched MEDLINE, Embase, Cochrane CENTRAL, and grey literature (July 23, 2019)
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells   +9 more
doaj   +1 more source